

# Initiation of Sodium-Glucose Cotransporter 2 inhibitors after first hospitalization for heart failure: a population-based cohort study

**First published:** 20/03/2025

**Last updated:** 20/03/2025

Study

Planned

## Administrative details

### PURI

<https://redirect.ema.europa.eu/resource/1000000378>

---

### EU PAS number

EUPAS1000000378

---

### Study ID

1000000378

---

### DARWIN EU® study

No

---

## Study countries

France

---

## Study description

This study aims to describe SGLT-2i initiation after discharge from first heart failure hospitalization in France between 2021 and 2023.

---

## Study status

Planned

# Research institutions and networks

## Institutions

### Toulouse University Hospital

**First published:** 01/02/2024

**Last updated:** 01/02/2024

**Institution**

### University Toulouse III

France

**First published:** 01/02/2024

**Last updated:** 01/02/2024

**Institution**

**Educational Institution**

# Pharmacologie En Population cohorteS biobanqueS (PEPSS), Hopitaux de Toulouse

France

**First published:** 31/03/2022

**Last updated:** 01/07/2024

**Institution**

Educational Institution

Hospital/Clinic/Other health care facility

ENCePP partner

## Contact details

### Study institution contact

Maryse LAPEYRE-MESTRE

Study contact

[maryse.lapeyre-mestre@univ-tlse3.fr](mailto:maryse.lapeyre-mestre@univ-tlse3.fr)

### Primary lead investigator

Paul Gautier

Primary lead investigator

### ORCID number:

0009-0008-9934-8432

## Study timelines

### Date when funding contract was signed

Planned: 01/11/2024

Actual: 01/11/2024

---

### **Study start date**

Planned: 14/11/2024

---

### **Data analysis start date**

Planned: 14/12/2024

---

### **Date of final study report**

Planned: 01/02/2024

## Sources of funding

- No external funding

## Regulatory

### **Was the study required by a regulatory body?**

No

---

### **Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

### Study type list

**Study topic:**

Human medicinal product

---

**Study type:**

Non-interventional study

---

**Scope of the study:**

Drug utilisation

**Data collection methods:**

Secondary use of data

---

**Study design:**

Cohort study of patients discharged from first hospitalization for heart failure between 2021 and 2023.

**Main study objective:**

Proportion of SGLT-2i initiation at 30 days after discharge.

## Study Design

**Non-interventional study design**

Cohort

## Study drug and medical condition

**Name of medicine**

DAPAGLIFLOZIN

---

**Name of medicine, other**

Empagliflozin

---

**Study drug International non-proprietary name (INN) or common name**

DAPAGLIFLOZIN

EMPAGLIFLOZIN

---

**Anatomical Therapeutic Chemical (ATC) code**

(A10BK) Sodium-glucose co-transporter 2 (SGLT2) inhibitors

Sodium-glucose co-transporter 2 (SGLT2) inhibitors

---

**Medical condition to be studied**

Cardiac failure

## Population studied

**Short description of the study population**

Patients > 18 years discharged from first hospitalization for heart failure between 2021 and 2023

---

**Age groups**

Adult and elderly population ( $\geq 18$  years)

---

**Special population of interest**

Renal impaired

---

**Special population of interest, other**

Diabetes

---

## Estimated number of subjects

300000

## Study design details

### Comparators

Not applicable.

---

### Outcomes

SGLT-2i initiation in the 30 days following hospital discharge.

## Data management

### Data sources

#### Data source(s)

Système National des Données de Santé (French national health system main database)

---

#### Data sources (types)

[Administrative healthcare records \(e.g., claims\)](#)

### Use of a Common Data Model (CDM)

#### CDM mapping

No

### Data quality specifications

**Check conformance**

Yes

---

**Check completeness**

Yes

---

**Check stability**

Yes

---

**Check logical consistency**

Yes

## Data characterisation

**Data characterisation conducted**

Not applicable